NCT03304964 - A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 21, 2017

Primary Completion Date

June 1, 2018

Study Completion Date

July 1, 2018

Conditions

Healthy

Interventions

DRUG

FP-025 (MMP-12 inhibitor)

Treatment A: 14 oral doses of 100 mg FP-025 (n=6) or placebo (n=2) in 8 days.

DRUG

FP-025 (MMP-12 inhibitor)

Treatment B: 14 oral doses of 200 mg FP-025 (n=6) or placebo (n=2) in 8 days.

DRUG

FP-025 (MMP-12 inhibitor)

Treatment C: 14 oral doses of 400 mg FP-025 (n=6) or placebo (n=2) in 8 days.

DRUG

FP-025 (MMP-12 inhibitor)

Treatment D: single oral dose of 200 mg FP-025 under fasted conditions.

DRUG

FP-025 (MMP-12 inhibitor)

Treatment E: single oral dose of 200 mg FP-025 after intake of a high-fat, high-calorie breakfast (fed condition).

Trial Locations (1)

QPS Netherlands B.V., Petrus Campersingel 123